44.22
+0.75(+1.73%)
Currency In USD
| Previous Close | 43.47 |
| Open | 43.48 |
| Day High | 44.45 |
| Day Low | 42.85 |
| 52-Week High | 60.37 |
| 52-Week Low | 37.02 |
| Volume | 1.27M |
| Average Volume | 738,269 |
| Market Cap | 4.08B |
| PE | -6.96 |
| EPS | -6.35 |
| Moving Average 50 Days | 49.86 |
| Moving Average 200 Days | 47.9 |
| Change | 0.75 |
If you invested $1000 in Ultragenyx Pharmaceutical Inc. (RARE) 10 years ago, it would be worth $897.5 as of December 21, 2024 at a share price of $44.22. Whereas If you bought $1000 worth of Ultragenyx Pharmaceutical Inc. (RARE) shares 5 years ago, it would be worth $981.79 as of December 21, 2024 at a share price of $44.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)
GlobeNewswire Inc.
Yesterday at 8:00 AM GMT
LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, today announced that N
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
GlobeNewswire Inc.
Dec 19, 2024 9:05 PM GMT
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced t
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
GlobeNewswire Inc.
Dec 19, 2024 1:00 PM GMT
If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type ANOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the submission of a Biologics License A